ALNY stock icon

Alnylam Pharmaceuticals

283.32 USD
+5.89
2.12%
Updated Nov 11, 12:10 PM EST
1 day
2.12%
5 days
5.53%
1 month
-0.35%
3 months
4.86%
6 months
89.02%
Year to date
45.34%
1 year
71.70%
5 years
206.46%
10 years
187.72%
 

About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Employees: 2,100

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 24 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

72% more capital invested

Capital invested by funds: $17B [Q1] → $29.3B (+$12.3B) [Q2]

43% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 61

17% more call options, than puts

Call options by funds: $703M | Put options by funds: $600M

16% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 164

5% more funds holding

Funds holding: 488 [Q1] → 514 (+26) [Q2]

4.98% more ownership

Funds ownership: 90.41% [Q1] → 95.39% (+4.98%) [Q2]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q1] → 6 (-2) [Q2]

Research analyst outlook

24 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$220
22%
downside
Avg. target
$323
14%
upside
High target
$400
41%
upside

24 analyst ratings

21 positive
88%
neutral
13%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
48% 1-year accuracy
72 / 150 met price target
41%upside
$400
Buy
Reiterated
4 Nov 2024
Raymond James
Gary Nachman
86% 1-year accuracy
12 / 14 met price target
5%upside
$298
Outperform
Maintained
1 Nov 2024
RBC Capital
Luca Issi
40% 1-year accuracy
21 / 53 met price target
6%upside
$300
Outperform
Reiterated
1 Nov 2024
Scotiabank
Greg Harrison
58% 1-year accuracy
14 / 24 met price target
9%upside
$310
Sector Outperform
Maintained
1 Nov 2024
Barclays
Gena Wang
39% 1-year accuracy
11 / 28 met price target
16%upside
$329
Overweight
Maintained
1 Nov 2024

Financial journalist opinion

Based on 16 articles about ALNY published over the past 30 days

Charts implemented using Lightweight Charts™